Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Autosomal dominant hypercholesterolemia (ADH; OMIM144400), a risk factor for coronary heart disease, is characterized by an increase in low-density lipoprotein cholesterol levels that is associated with mutations in the genes LDLR (encoding low-density lipoprotein receptor) or APOB (encoding apolipoprotein B). We mapped a third locus associated with ADH, HCHOLA3 at 1p32, and now report two mutations in the gene PCSK9 (encoding proprotein convertase subtilisin/kexin type 9) that cause ADH. PCSK9 encodes NARC-1 (neural apoptosis regulated convertase), a newly identified human subtilase that is highly expressed in the liver and contributes to cholesterol homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mutations conveying gain or loss of function of PCSK9 result in a higher or lower level of LDL cholesterol, respectively, which in turn is associated with a corresponding higher 7 or lower 6 risk of incident coronary heart disease.”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [7]
In the citing paper
“In 2003, Abifadel and colleagues identified gain-of-function mutations in the PCSK9 gene causative of familial hypercholesterolemia, an autosomal dominant trait characterized by an elevation in circulating low-density lipoprotein cholesterol (LDL-C) and premature coronary heart disease (CHD) risk (2).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [2]
In the citing paper
“Autosomal Dominant Hypercholesterolemia (ADH), due to mutations in the LDLR, APOB or PCSK9 genes, is characterized by an isolated elevation of cholesterol due to high levels of low-density lipoproteins (LDL).”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“ADH is genetically heterogeneous and associated with mutations in the well-known LDLR (low density lipoprotein receptor) (FH, OMIM #606945), APOB (apolipoprotein B-100) (FDB, OMIM # 144010) and PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9, Abifadel M et al. 2003) genes.”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the subtilisin family of proprotein convertases (PCs) [2], with an established role in the systemic control of blood cholesterol and a lesser-characterized role in neuronal development and apoptosis [3,4].”
From PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling (2012) · cites this paper as [3]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
RGD AND OTHER RECOGNITION SEQUENCES FOR INTEGRINS
Ruoslahti, E. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.697 · Cited by 3,191
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Self-citationA proteolytic pathway that controls the cholesterol content of membranes, cells, and blood
Brown, M. S., & Goldstein, J. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11041 · Cited by 1,134
A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32
Varret, M., Rabès, J.-P., Saint-Jore, B., Cenarro, A., Marinoni, J.-C., Civeira, F., Devillers, M., Krempf, M., Coulon, M., Thiart, R., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302370 · Cited by 175
Self-citationBiosynthesis and Cellular Trafficking of the Convertase SKI-1/S1P
Elagoz, A., Benjannet, S., Mammarbassi, A., Wickham, L., & Seidah, N. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109011200 · Cited by 113
Self-citationHunt, S. C., Hopkins, P. N., Bulka, K., McDermott, M. T., Thorne, T. L., Wardell, B. B., Bowen, B. R., Ballinger, D. G., Skolnick, M. H., & Samuels, M. E. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.4.1089 · Cited by 109
Cited by
Items 1,001–1,044 of 1,044
Insights into obesity and diabetes at the intersection of mouse and human genetics
Kebede, M. A., & Attie, A. D. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.06.006 · Cited by 35
Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin
Susan-Resiga, D., Girard, E., Essalmani, R., Roubtsova, A., Marcinkiewicz, J., Derbali, R. M., Evagelidis, A., Byun, J. H., Lebeau, P. F., Austin, R. C., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101177 · Cited by 34
“This suggests that the atheroprotective effects of ASGR1 del12 go beyond the lowering of serum LDLc. J. Biol.”
BackgroundSelf-citationPathways and Molecular Mechanisms Governing LDL Receptor Regulation
Schmidt, H. M., Jarrett, K. E., de Aguiar Vallim, T. Q., & Tarling, E. J. (2025) · Circulation Research · doi:10.1161/circresaha.124.323578 · Cited by 33
LDL Receptor Pathway Regulation by miR-224 and miR-520d
Salerno, A. G., van Solingen, C., Scotti, E., Wanschel, A. C. B. A., Afonso, M. S., Oldebeken, S. R., Spiro, W., Tontonoz, P., Rayner, K. J., & Moore, K. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00081 · Cited by 33
“CAD remains the number one cause of morbidity and mortality in the United States (32), and new therapies are urgently needed to reduce the burden of disease.”
BackgroundInfluentialPCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
Sobati, S., Shakouri, A., Edalati, M., Mohammadnejad, D., Parvan, R., Masoumi, J., & Abdolalizadeh, J. (2020) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2020.062 · Cited by 33
Therapeutic targets of triglyceride metabolism as informed by human genetics
Bauer, R. C., Khetarpal, S. A., Hand, N. J., & Rader, D. J. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.005 · Cited by 32
Endocytic adaptors Arh and Dab2 control homeostasis of circulatory cholesterol
Tao, W., Moore, R., Meng, Y., Smith, E. R., & Xu, X.-X. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m063065 · Cited by 32
Singh, A. B., Li, H., Kan, C. F. K., Dong, B., Nicolls, M. R., & Liu, J. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.301131 · Cited by 32
Lei, J. (2014) · Medical Science Monitor · doi:10.12659/msm.892091 · Cited by 32
“Allard D, Amsellem S, Abifadel M et al: Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.”
BackgroundInfluentialLee, J. S., O’Connell, E. M., Pacher, P., & Lohoff, F. W. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081758 · Cited by 31
“In line with preclinical findings, genetic studies have reported that gain-of-function mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia [88], while loss-of-function mutations in the PCSK9 gene are closely associated with low LDL-C levels and reduced risk of coronary heart disease (CHD) [89,90].”
BackgroundElbitar, S., Khoury, P. E., Ghaleb, Y., Rabès, J.-P., Varret, M., Seidah, N. G., Boileau, C., & Abifadel, M. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1206080 · Cited by 29
Self-citationShibata, N., Ohnuma, T., Higashi, S., Higashi, M., Usui, C., Ohkubo, T., Watanabe, T., Kawashima, R., Kitajima, A., Ueki, A., et al. (2005) · Psychiatric Genetics · doi:10.1097/00041444-200512000-00004 · Cited by 28
“Genetic mutations in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene on the chromosome 1p cause susceptibility to autosomal dominant hypercholesterolemia (Abifadel et al., 2003; Leren, 2004; Timms et al., 2004).”
BackgroundSasaki, M., Terao, Y., Ayaori, M., Uto-Kondo, H., Iizuka, M., Yogo, M., Hagisawa, K., Takiguchi, S., Yakushiji, E., Nakaya, K., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.302670 · Cited by 28
Durairaj, A., Sabates, A., Nieves, J., Moraes, B., & Baum, S. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0556-0 · Cited by 27
Monogenic and Polygenic Models of Coronary Artery Disease
Muse, E. D., Chen, S.-F., & Torkamani, A. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01540-0 · Cited by 27
New Loss-of-Function Mutations in PCSK9 Reduce Plasma LDL Cholesterol
Meng, F.-H., Liu, S., Xiao, J., Zhou, Y.-X., Dong, L.-W., Li, Y.-F., Zhang, Y.-Q., Li, W.-H., Wang, J.-Q., Wang, Y., et al. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.122.318839 · Cited by 27
Loss-of-function PCSK9 mutations are not associated with Alzheimer disease
Paquette, M., Saavedra, Y. G. L., Poirier, J., Théroux, L., Dea, D., Baass, A., & Dufour, R. (2018) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988718764330 · Cited by 26
Aherrahrou, R., Reinberger, T., Hashmi, S., & Erdmann, J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae161 · Cited by 25
Identifying therapeutic drug targets using bidirectional effect genes
Estrada, K., Froelich, S., Wuster, A., Bauer, C. R., Sterling, T., Clark, W. T., Ru, Y., Trinidad, M., Nguyen, H. P., Luu, A. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21843-8 · Cited by 25
Expression and localization of PCSK9 in rat hepatic cells
Grozdanov, P. N., Petkov, P. M., Karagyozov, L. K., & Dabeva, M. D. (2006) · Biochemistry and Cell Biology · doi:10.1139/o05-155 · Cited by 25
A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22
Cenarro, A., García-Otín, A.-L., Tejedor, M., Solanas, M., Jarauta, E., Junquera, C., Ros, E., Mozas, P., Puzo, J., Pocoví, M., et al. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2010.01485.x · Cited by 25
Fu, T., Guan, Y., Xu, J., & Wang, Y. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.05.002 · Cited by 25
Mayne, J., Ooi, T. C., Tepliakova, L., Seebun, D., Walker, K., Mohottalage, D., Ning, Z., Abujrad, H., Mbikay, M., Wassef, H., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00777 · Cited by 24
Roubtsova, A., Garçon, D., Lacoste, S., Chamberland, A., Marcinkiewicz, J., Métivier, R., Sotin, T., Paquette, M., Bernard, S., Cariou, B., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159217 · Cited by 22
Self-citationTargeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol
Newman, C. B., & Tobert, J. A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac708 · Cited by 20
Lipids, lipid-lowering therapy, and neuropathy: a narrative review
Pasha, R., Azmi, S., Ferdousi, M., Kalteniece, A., Bashir, B., Gouni-Berthold, I., Malik, R. A., & Soran, H. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.03.013 · Cited by 18
Gosselin, N. H., Schuck, V. J. A., Barriere, O., Kulmatycki, K., Margolskee, A., Smith, P., & He, Y. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2774 · Cited by 17
“PCSK9 as a target for reducing LDL- C has been validated both by genetic evidence in humans and pharmacotherapy with antiPCSK9 monoclonal antibodies.(8,10) Inclisiran is a novel small- interfering ribonucleic acid (siRNA) therapy that is designed to specifically target PCSK9 mRNA in the liver for the treatment of hype…”
BackgroundRodríguez‐Pérez, C., Ramprasath, V. R., Pu, S., Sabra, A., Quirantes‐Piné, R., Segura‐Carretero, A., & Jones, P. J. (2016) · Lipids · doi:10.1007/s11745-015-4099-4 · Cited by 16
PCSK9 Mediates Dyslipidemia Induced by Olanzapine Treatment in Schizophrenia Patients
Huang, J., Xiao, J., Peng, Z., Shao, P., Sun, M., Long, Y., Wang, X., Shen, M., Kang, D., Yang, Y., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06042-z · Cited by 16
“Individuals with several PCSK9 variants are predisposed to be “gain-of-function” carriers to hypercholesterolemia (Abifadel et al. 2003; Humphries et al. 2006), while nonsense and several missense PCSK9 variants were associated with “loss-of-function” hypocholesterolemia (Cohen et al.”
BackgroundAttie, A. D. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000137288.82390.04 · Cited by 16
Tomlinson, B., Chow, E., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.2029402 · Cited by 15
“a cause for familial hypercholesterolemia (FH) was a major breakthrough in the understanding of lipid pathways [7].”
BackgroundHuman genetic insights into lipoproteins and risk of cardiometabolic disease
Stitziel, N. O. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000389 · Cited by 14
Mousavi, S. A., Berge, K. E., Berg, T., & Leren, T. P. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08219.x · Cited by 14
Martinelli, L., Adamopoulos, A., Johansson, P., Wan, P. T., Gunnarsson, J., Guo, H., Boyd, H., Zelcer, N., & Sixma, T. K. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014349 · Cited by 14
Neuronal PCSK9 regulates cognitive performances via the modulation of ApoER2 synaptic localization
Pelucchi, S., Da Dalt, L., De Cesare, G., Stringhi, R., D’Andrea, L., La Greca, F., Cambria, C., Vandermeulen, L., Zianni, E., Musardo, S., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107652 · Cited by 12
Mansoor, T., Rao, B. H., Gupta, K., Parikh, S. S., Abramov, D., Mehta, A., Al Rifai, M., Virani, S. S., Nambi, V., Minhas, A. M. K., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00712-x · Cited by 12
“The role of PCSK9 in cholesterol metabolism regulation was first identified in 2003, initiating the journey toward its manipulation to regulate LDL-C levels [42, 43].”
Korthauer, L. E., Giugliano, R. P., Guo, J., Sabatine, M. S., Sever, P., Keech, A., Atar, D., Kurtz, C., Ruff, C. T., Mach, F., et al. (2022) · PLOS ONE · doi:10.1371/journal.pone.0266615 · Cited by 11
“PCSK9 is primarily expressed in the liver, where it binds the low-density lipoprotein receptor on the surface of hepatocytes [2].”
Backgroundvan Solingen, C., Oldebeken, S. R., Salerno, A. G., Wanschel, A. C. B. A., & Moore, K. J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.667298 · Cited by 11
Reducing elevated plasma LDL cholesterol: the central role of the LDL receptor
Vincent, J. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.95 · Cited by 10
Insights from population-based analyses of plasma lipids across the allele frequency spectrum
Peloso, G. M., & Natarajan, P. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.01.003 · Cited by 10
Zheng, X., Yuan, W., Li, L., Ma, H., Zhu, M., Li, X., & Feng, X. (2025) · European Journal of Medical Research · doi:10.1186/s40001-025-02937-1 · Cited by 9
“…in different ways in humans, including the removal of N-terminal acidic stretch (amino acids 31– 53 ) within the prodomain of PCSK9i were discovered to be a novel kind of lipid-lowering drugs, which blocked the interaction between PCSK9 and LDLR, preventing LDLR degradation in hepatocytes [35].”
Ference, B. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1163 · Cited by 8
“Rare gain- offunction mutations in the PCSK9 gene cause markedly elevated plasma LDL- C levels resulting in the clinical phenotype of autosomal dominant familial hypercholesterolemia.(23) By contrast, rare lossoffunction and lowfrequency partial loss- offunction mutations in the PCSK9 gene result in modestly lower pla…”
BackgroundAnalyses of PCSK9 Post-translational Modifications Using Time-of-Flight Mass Spectrometry
Dewpura, T., & Mayne, J. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61779-204-5_8 · Cited by 8
Wang, J. D. J., Teo, A. Y. T., Xiao, B., Chao, Y., Zhou, Z. D., Tan, B. J.-W., Chan, L.-L., Rosalie, E., & Tan, E.-K. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00568-y
Metadata
- Authors
- Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J.-M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., & Boileau, C.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Genoscope (FR)
- Montreal Clinical Research Institute (CA)
- Pitié-Salpêtrière Hospital (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Hôpital Claude Huriez (FR)
- Hospices Civils de Lyon (FR)
- ORCID
- Venue
- Nature Genetics
- Published
- 2003-05-05
- Volume
- 34
- Issue
- 2
- Pages
- 154-156
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2040612932
- Semantic Scholar
- 80bf33c74bfe780bcc1968f318b09647e59f0afe
- Cited by
- 2,985
- References
- 6
- Citations by year
- 2026: 88 · 2025: 115 · 2024: 154 · 2023: 175 · 2022: 163 · 2021: 207 · 2020: 182 · 2019: 173 · 2018: 214 · 2017: 232 · 2016: 214 · 2015: 200 · 2014: 162 · 2013: 131 · 2012: 101
- FWCI
- 38.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Institut National de la Santé et de la Recherche Médicale
- Fondation de France
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- PCSK9, autosomal dominant hypercholesterolemia, LDL receptor, apolipoprotein B, LDL cholesterol, genetic mutations, cholesterol homeostasis, subtilases, coronary heart disease risk
- MeSH terms
- Proprotein Convertase 9, Chromosomes, Human, Pair 1, Female, Genes, Dominant, Humans, Hyperlipoproteinemia Type II, Genetic Linkage, Liver, Male, Mutation, Pedigree, Serine Endopeptidases, Amino Acid Substitution, Proprotein Convertases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.